Rare Disease Reach There is a large underserved market of undiagnosed rare disease patients (over 400 million globally) with long diagnostic timelines, presenting an opportunity to expand Probably Genetic's direct-to-consumer testing and accelerated diagnosis services to improve patient outcomes and capture early adopter customers.

Partnership Potential Existing and past collaborations with foundations and pharma (APBDRF, X4 Pharmaceuticals, SynGAP Research Fund) indicate a strong partner-friendly model that can be scaled to secure additional sponsored testing programs and co-branded patient access initiatives.

No-Cost Testing Model The no-cost and sponsored testing programs for neurodegenerative, dementia, and genetic immunodeficiencies demonstrate a viable pathway to broaden payer-agnostic access, enabling growth through volume and later monetization avenues such as data partnerships and targeted therapies.

Clinical and Pharma Alignment Strategic alignment with drug developers seeking genetic insights suggests opportunities to offer diagnostic-enrichment services, patient recruitment support, and companion testing programs that accelerate clinical trials and improve trial enrollment quality.

Tech-Driven Advantage Robust AI-driven symptom checking and rapid genetic testing capabilities positioned on cloud and modern tech stack offer a differentiator for scaled onboarding of patients, enabling faster lead-to-diagnosis conversion and higher retention for ongoing advocacy and treatment connections.